Biomaterial Database

Amphotericin B nephrotoxicity. 1988

J R Raymond

Duke University Medical Center, Durham, North Carolina.

Nephrotoxicity becomes apparent days to months after the institution of amphotericin B therapy. It is characterized by azotemia, decreased renal plasma flow, decreased glomerular filtration rate, tubular defects, nephrocalcinosis, and diffuse, nonspecific histologic changes. Management consists of minimizing exposure to other nephrotoxins and ensuring adequate hydration.

UI	MeSH Term	Description	Entries
D007674	Kidney Diseases	Pathological processes of the KIDNEY or its component tissues.	Disease, Kidney,Diseases, Kidney,Kidney Disease
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000666	Amphotericin B	Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.	Amphocil,Amphotericin,Amphotericin B Cholesterol Dispersion,Amphotericin B Colloidal Dispersion,Fungizone

Related Publications

J R Raymond

Amphotericin B nephrotoxicity.

January 1990, Drug safety,

J R Raymond

Amphotericin B nephrotoxicity.

January 2002, Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia,

J R Raymond

Amphotericin B nephrotoxicity.

February 2002, The Journal of antimicrobial chemotherapy,

J R Raymond

[Nephrotoxicity of amphotericin B].

January 2002, Nephrologie,

J R Raymond

Nephrotoxicity of amphotericin B.

September 1994, Journal of the American College of Surgeons,

J R Raymond

Nephrotoxicity of amphotericin B desoxycholate.

September 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,